{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:49Z","timestamp":1772121229246,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.medmal.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T10:57:39Z","timestamp":1601722659000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical trial protocols of repurposed prophylaxis for COVID-19: A review"],"prefix":"10.1016","volume":"51","author":[{"given":"E.","family":"Sallard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Belhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-X.","family":"Lescure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Peiffer-Smadja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2020.09.013_bib0270","series-title":"John Hopkins University coronavirus resource center","year":"2020"},{"issue":"8","key":"10.1016\/j.medmal.2020.09.013_bib0275","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmi.2020.05.019","article-title":"Review of trials currently testing treatment and prevention of COVID-19","volume":"26","author":"Fragkou","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-014-0253-5","article-title":"Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis","volume":"12","author":"Krakower","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.medmal.2020.09.013_bib0285","series-title":"Home","year":"2020"},{"key":"10.1016\/j.medmal.2020.09.013_bib0290","series-title":"EU clinical trials register","year":"2020"},{"issue":"9","key":"10.1016\/j.medmal.2020.09.013_bib0295","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/jac\/dkaa223","article-title":"Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19","volume":"75","author":"Peiffer-Smadja","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2020.09.013_bib0300","unstructured":"elise. Covid-19 - Living NMA [Internet]. Covid-19 - Living NMA. [cited 2020 Apr 28]. Available from: https:\/\/covid-nma.com\/."},{"issue":"6","key":"10.1016\/j.medmal.2020.09.013_bib0305","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A real-time dashboard of clinical trials for COVID-19","volume":"2","author":"Thorlund","year":"2020","journal-title":"Lancet Digit Health"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.medmal.2020.09.013_bib0315","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0320","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.013_bib0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"issue":"15","key":"10.1016\/j.medmal.2020.09.013_bib0335","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0340","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioScience Trends"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0345","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2020.09.013_bib0350","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.013_bib0355","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.120.048238","article-title":"Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database","volume":"142","author":"Nguyen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.medmal.2020.09.013_bib0360","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.medmal.2020.09.013_bib0365","article-title":"Differential COVID-19-attributable mortality and BCG vaccine use in countries","author":"Shet","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.medmal.2020.09.013_bib0370","article-title":"Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing","author":"Hensel","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.medmal.2020.09.013_bib0375","article-title":"Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19","author":"Franklin","year":"2020","journal-title":"MedRxiv"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.013_bib0380","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.medmal.2020.09.013_bib0385","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects. Low D, editor","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.medmal.2020.09.013_bib0390","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Long-term safety and durable antiretroviral activity of lopinavir\/ritonavir in treatment-naive patients: 4 year follow-up study","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2020.09.013_bib0395","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","volume":"178","author":"Sallard","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2020.09.013_bib0400","article-title":"Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients","author":"Hadjadj","year":"2020","journal-title":"MedRxiv"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.013_bib0405","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1001","article-title":"Pegylated interferon-\u03b1 protects type 1 pneumocytes against SARS coronavirus infection in macaques","volume":"10","author":"Haagmans","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.medmal.2020.09.013_bib0410","article-title":"Interferon-a2b treatment for COVID-19","author":"Zhou","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.medmal.2020.09.013_bib0415","article-title":"An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area","author":"Meng","year":"2020","journal-title":"MedRxiv"},{"issue":"3","key":"10.1016\/j.medmal.2020.09.013_bib0420","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1128\/JVI.79.3.1966-1969.2005","article-title":"Nitric oxide inhibits the replication cycle of Severe Acute Respiratory Syndrome Coronavirus","volume":"79","author":"\u00c5kerstr\u00f6m","year":"2005","journal-title":"JVI"},{"key":"10.1016\/j.medmal.2020.09.013_bib0425","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.medmal.2020.09.013_bib0430","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.medmal.2020.09.013_bib0435","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/jp102619w","article-title":"Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes","volume":"114","author":"Villala\u00edn","year":"2010","journal-title":"J Phys Chem B"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0440","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against coronavirus disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.medmal.2020.09.013_bib0445","article-title":"Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study","author":"Lane","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.medmal.2020.09.013_bib0450","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0455","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13102818.2020.1775118","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens","volume":"34","author":"Momekov","year":"2020","journal-title":"Biotechnology & Biotechnological Equipment"},{"key":"10.1016\/j.medmal.2020.09.013_bib0460","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jopr.13209","article-title":"Rapid in-vitro inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse","volume":"29","author":"Bidra","year":"2020","journal-title":"J Prosthodont"},{"issue":"4","key":"10.1016\/j.medmal.2020.09.013_bib0465","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.medmal.2020.09.013_bib0470","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0475","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.medmal.2020.09.013_bib0480","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"10.1016\/j.medmal.2020.09.013_bib0485","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2020.09.013_bib0490","unstructured":"IDSA COVID-19 guidelines. [Internet]. Available from: https:\/\/www.idsociety.org\/practice- guideline\/covid-19-guideline-treatment-and-management."},{"issue":"6506","key":"10.1016\/j.medmal.2020.09.013_bib0495","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.medmal.2020.09.013_bib0500","first-page":"e02015","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Gallagher T, editor","volume":"94","author":"Wan","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.medmal.2020.09.013_bib0505","doi-asserted-by":"crossref","first-page":"m1328","DOI":"10.1136\/bmj.m1328","article-title":"Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal","volume":"369","author":"Wynants","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.medmal.2020.09.013_bib0510","article-title":"Pharmacologic treatments for COVID-19: a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.medmal.2020.09.013_bib0515","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16814","article-title":"Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients","volume":"190","author":"Lanza","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medmal.2020.09.013_bib0520","series-title":"Recommendations for investigational COVID-19 convalescent plasma","year":"2020"},{"issue":"6506","key":"10.1016\/j.medmal.2020.09.013_bib0525","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"issue":"541","key":"10.1016\/j.medmal.2020.09.013_bib0530","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20307113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X20307113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:37:26Z","timestamp":1760078246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X20307113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0399077X20307113"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2020.09.013","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.30.20117937","asserted-by":"object"}]},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial protocols of repurposed prophylaxis for COVID-19: A review","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}